The effect of comorbidities for the prognosis of community-acquired pneumonia: an epidemiologic study using a hospital surveillance in Japan

Epidemiologic Study ◽

Severe Pneumonia ◽

Term Outcome ◽

Long Term Outcome ◽

Chronic Pulmonary Diseases ◽

History Of ◽

Abstract Objective Pneumonia is a common but serious illness that continues to present significant morbidity and mortality. Although the effect of severity at admission on outcome has been well reported, the role of comorbidity is still not widely understood. The Charlson Comorbidity Index measures comorbidity with a well-established history of predicting long-term outcome but its utility in pneumonia prognosis is still limited. Here, we use the Charlson Comorbidity Index and hospital surveillance data to investigate associations between comorbidities and in-hospital mortality due to community-acquired pneumonia.Results Among the 535 eligible adult patients (69.0% male, median [IQR] age, 79 [70-84] years), 100 (18.7%) acquired severe to extremely severe pneumonia. The median [IQR] CCI was 1[1-3]. Malignancy (129 of 535, 24.1%), chronic pulmonary diseases (113 of 535, 21.1%) and congestive heart failure (103 of 535, 19.3%) were frequent. Higher Charlson Comorbidity Index scores were associated with higher risk of in-hospital mortality (OR 1.28; 95% CI 1.07-1.53). These results support the inclusion of comorbid burden in predicting community-acquired pneumonia outcome.

The effect of comorbidities for the prognosis of community-acquired pneumonia: an epidemiologic study using a hospital surveillance in Japan

BMC Research Notes ◽

10.1186/s13104-019-4848-1 ◽

2019 ◽

Vol 12 (1) ◽

Author(s):

Mai Thi Ngoc Nguyen ◽

Nobuyuki Saito ◽

Yukiko Wagatsuma

Keyword(s):

Hospital Mortality ◽

Epidemiologic Study ◽

Severe Pneumonia ◽

Term Outcome ◽

Long Term Outcome ◽

Chronic Pulmonary Diseases ◽

History Of ◽

Abstract Objective Pneumonia is a common but serious illness that continues to present significant morbidity and mortality. Although the effect of severity at admission on outcome has been well reported, the role of comorbidity is still not widely understood. The Charlson Comorbidity Index measures comorbidity with a well-established history of predicting long-term outcome but its utility in pneumonia prognosis is still limited. Here, we use the Charlson Comorbidity Index and hospital surveillance data to investigate associations between comorbidities and in-hospital mortality due to community-acquired pneumonia. Results Among the 535 eligible adult patients (69.0% male, median [IQR] age, 79 [70–84] years), 100 (18.7%) acquired severe to extremely severe pneumonia. The median [IQR] CCI was 1 [1–3]. Malignancy (129 of 535, 24.1%), chronic pulmonary diseases (113 of 535, 21.1%) and congestive heart failure (103 of 535, 19.3%) were frequent. Higher Charlson Comorbidity Index scores were associated with higher risk of in-hospital mortality (OR 1.28; 95% CI 1.07–1.53). These results support the inclusion of comorbid burden in predicting community-acquired pneumonia outcome.

The effect of comorbidities for the prognosis of community-acquired pneumonia: an epidemiologic study using a hospital surveillance in Japan

10.21203/rs.2.16128/v2 ◽

2019 ◽

Author(s):

Mai Thi Ngoc Nguyen ◽

Nobuyuki Saito ◽

Yukiko Wagatsuma

Keyword(s):

Hospital Mortality ◽

Epidemiologic Study ◽

Severe Pneumonia ◽

Term Outcome ◽

Long Term Outcome ◽

Chronic Pulmonary Diseases ◽

History Of ◽

Abstract Objective Pneumonia is a common but serious illness that continues to present significant morbidity and mortality. Although the effect of severity at admission on outcome has been well reported, the role of comorbidity is still not widely understood. The Charlson Comorbidity Index measures comorbidity with a well-established history of predicting long-term outcome but its utility in pneumonia prognosis is still limited. Here, we use the Charlson Comorbidity Index and hospital surveillance data to investigate associations between comorbidities and in-hospital mortality due to community-acquired pneumonia.Results Among the 535 eligible adult patients (69.0% male, median [IQR] age, 79 [70-84] years), 100 (18.7%) acquired severe to extremely severe pneumonia. The median [IQR] CCI was 1[1-3]. Malignancy (129 of 535, 24.1%), chronic pulmonary diseases (113 of 535, 21.1%) and congestive heart failure (103 of 535, 19.3%) were frequent. Higher Charlson Comorbidity Index scores were associated with higher risk of in-hospital mortality (OR 1.28; 95% CI 1.07-1.53). These results support the inclusion of comorbid burden in predicting community-acquired pneumonia outcome.

Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer

European Journal of Cardio-Thoracic Surgery ◽

10.1016/j.ejcts.2005.06.046 ◽

2005 ◽

Vol 28 (5) ◽

pp. 759-762 ◽

Cited By ~ 145

Author(s):

O BIRIM ◽

A KAPPETEIN ◽

A BOGERS

Keyword(s):

Lung Cancer ◽

Cell Lung Cancer ◽

Nonsmall Cell Lung Cancer ◽

Term Outcome ◽

Long Term Outcome ◽

Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer

Annals of Surgical Oncology ◽

10.1245/s10434-017-6079-9 ◽

2017 ◽

Vol 24 (12) ◽

pp. 3692-3699 ◽

Cited By ~ 11

Author(s):

Annett Kahl ◽

Andreas du Bois ◽

Philipp Harter ◽

Sonia Prader ◽

Stephanie Schneider ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Prognostic Value ◽

Term Outcome ◽

Long Term Outcome ◽

Primary Epithelial Ovarian Cancer ◽

Comorbidity Index ◽

Short And Long Term

Charlson Comorbidity Index and other predictors of in-hospital mortality among adults with community-acquired pneumonia

Jornal Brasileiro de Pneumologia ◽

10.36416/1806-3756/e20200257 ◽

2021 ◽

Vol 47 (1) ◽

pp. e20200257-e20200257

Author(s):

Laura Fuchs Bahlis ◽

Luciano Passamani Diogo ◽

Sandra Costa Fuchs

Keyword(s):

Hospital Mortality ◽

The Charlson Comorbidity Index as a Predictor of Long-Term Outcome in Liver Transplantation: Single Centre Experience From the UK.

Transplantation Journal ◽

10.1097/00007890-201407151-02484 ◽

2014 ◽

Vol 98 ◽

pp. 729

Author(s):

S. Pathak ◽

J. Dixon ◽

J. Hutchinson ◽

R. Jones ◽

E. Hidalgo ◽

...

Keyword(s):

Liver Transplantation ◽

Single Centre ◽

Term Outcome ◽

Long Term Outcome ◽

Single Centre Experience ◽

Comorbidity Index ◽

The Uk

Drug-coated Balloons – History and Peripheral Vascular Opportunities

Interventional Cardiology Review ◽

10.15420/icr.2010.5.1.70 ◽

2010 ◽

Vol 5 (1) ◽

pp. 70

Author(s):

Bruno Scheller ◽

Bodo Cremers ◽

Stephanie Schmitmeier ◽

Beatrix Schnorr ◽

Yvonne Clever ◽

...

Keyword(s):

Arterial Disease ◽

Local Drug Delivery ◽

Term Outcome ◽

Long Term Outcome ◽

Late Lumen Loss ◽

Short Term Exposure ◽

History Of ◽

Area Of Concern ◽

Peripheral Arterial ◽

Drug Coated Balloon

One of the most innovative fields of modern medical research is the percutaneous transluminal treatment of vascular disease. During recent decades considerable advances have been made in intravascular interventions for the treatment of coronary and peripheral arterial disease. Despite these advances, the long-term outcome remains an area of concern in many applications. Restenosis is still a challenge in endovascular medicine and has thus been referred to as the Achilles’ heel of percutaneous intervention. Therefore, novel strategies have been developed to overcome this problem. These include drug-eluting stents and the more recently introduced non-stent-based local drug delivery systems (in particular the drug-coated balloon). Results from several pre-clinical and clinical studies indicate that short-term exposure of injured arteries to paclitaxel delivered from regular angioplasty balloons may be sufficient to reduce late lumen loss and restenosis rates during a critical period of time after the angioplasty of diseased coronary and peripheral arteries. Although the number of published trials and patients treated is still limited, data available seem to prove that restenosis inhibition by immediate drug release is feasible. This article reviews the history of the drug-coated balloon and then focuses on peripheral artery trials.

Benign paroxysmal vertigo of childhood: Long-term outcome

Cephalalgia ◽

10.1177/0333102410382797 ◽

2010 ◽

Vol 31 (4) ◽

pp. 439-443 ◽

Cited By ~ 31

Author(s):

Benjamin Krams ◽

Bernard Echenne ◽

Julie Leydet ◽

François Rivier ◽

Agathe Roubertie

Keyword(s):

Patient Outcome ◽

Complete Recovery ◽

Homogeneous Condition ◽

Term Outcome ◽

Long Term Outcome ◽

Family Medical History ◽

History Of ◽

Attacks Of Vertigo ◽

Epidemiological Link

Introduction Benign paroxysmal vertigo (BPV) is characterized by recurrent attacks of dizziness in a healthy child. Complete recovery typically takes place during childhood, and an epidemiological link with migraine has been pointed out. Nevertheless, data concerning long-term patient outcome are scarce. Subjects and methods We analyzed the clinical data of 17 patients diagnosed with BPV between 1991 and 2008 in our neuropediatric department; we particularly focused on family medical history and long-term patient outcome by reviewing their medical files and by interviewing the families with a standardized questionnaire administered by phone. Results Thirteen families responded to the questionnaire, performed 1.1 to 24.5 years after onset. Among 10 patients older than 11 years of age, five continue to suffer attacks of vertigo. Median age at recovery was six years. Nine subjects exhibited migraine, including all six aged 15 years or older. There was a first-degree history of migraine in eight out of 13 children. Conclusion BPV may not be a homogeneous condition, as some children have a poorer prognosis than others. The strong link with migraine, already noticed by previous authors, led us to discuss the pathophysiology of this condition.